August 1, 2017

July 30, 2017

The results are ground-breaking Alpha-Synuclein and Multiple System Atrophy. The often misdiagnosed as Parkinson’s, Multiple System Atrophy (MSA) is a rapidly progressive, fatal neurodegenerative...

July 2, 2017

The results are ground-breaking ICB International, Inc., (“ICBII”), has moved closer to halting Parkinson’s disease in patients. The Company has shown that its drug...

July 1, 2017

June 4, 2017

UPDATE ON PARKINSON’S “ROAD TO THE CURE” PROJECT John looked out the window, remembering better days. He could smell the scent of freshly baked banana...

May 14, 2017

WHY STEM CELL THERAPY MAY NOT BE THE ANSWER And stem-cell therapies have been associated with other adverse effects as well... such adverse effects are...

May 1, 2017

April 1, 2017

The Battle Against Parkinson’s Disease According to Ram Bhatt, PhD, CSO “ICBI continues to make progress in bringing its Parkinson’s drug nearer and nearer...

April 1, 2017

February 1, 2017

January 31, 2017

By:Ram S. Bhatt, PhD, CEO & CSO PROS AND CONS OF STEM CELL THERAPY PROS AND CONS OF STEM CELL THERAPY Back in...

December 31, 2016

“...the biologics (drugs) capable of modifying and/or halting the brain diseases are prevented from entering the brain... ICBII’s SMART Molecules … making it the...

December 1, 2016

We have a Material Transfer Agreement (MTA) with a large pharmaceutical company to affirm our efforts and findings in their laboratory. This process was...

December 1, 2016

November 1, 2016

ICBI SMART Molecules (SMs) technology is poised to translate our most promising scientific breakthroughs into meaningful disease altering treatments capable of tackling the most...